$14.30
1.06%
Nasdaq, Apr 21, 07:49 pm CET
ISIN
US15687V1098
Symbol
CERT

Certara Stock price

$14.15
+3.11 28.17% 1M
+2.58 22.30% 6M
+3.50 32.86% YTD
-2.80 16.52% 1Y
-6.40 31.14% 3Y
-23.93 62.84% 5Y
-23.93 62.84% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+0.62 4.58%
ISIN
US15687V1098
Symbol
CERT

Key metrics

Market capitalization $2.28b
Enterprise Value $2.42b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 30.66
EV/Sales (TTM) EV/Sales 6.28
P/S ratio (TTM) P/S ratio 5.93
P/B ratio (TTM) P/B ratio 2.15
Revenue growth (TTM) Revenue growth 8.70%
Revenue (TTM) Revenue $385.15m
EBIT (operating result TTM) EBIT $13.00m
Free Cash Flow (TTM) Free Cash Flow $78.84m
Cash position $179.18m
EPS (TTM) EPS $-0.08
P/E forward 1,886.67
P/S forward 5.43
EV/Sales forward 5.75
Short interest 5.07%
Show more

Is Certara a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Certara Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Certara forecast:

5x Buy
42%
7x Hold
58%

Analyst Opinions

12 Analysts have issued a Certara forecast:

Buy
42%
Hold
58%

Financial data from Certara

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
385 385
9% 9%
100%
- Direct Costs 208 208
12% 12%
54%
177 177
6% 6%
46%
- Selling and Administrative Expenses 59 59
7% 7%
15%
- Research and Development Expense 37 37
9% 9%
10%
81 81
16% 16%
21%
- Depreciation and Amortization 68 68
21% 21%
18%
EBIT (Operating Income) EBIT 13 13
7% 7%
3%
Net Profit -12 -12
78% 78%
-3%

In millions USD.

Don't miss a Thing! We will send you all news about Certara directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Certara Stock News

Negative
MarketBeat
about 6 hours ago
While the impact of unanticipated tariff policy changes in early April was market-wide, the recovery has been less even. Despite a major rebound following the sell-off, some firms have been sluggish to reclaim lost ground.
Neutral
GlobeNewsWire
7 days ago
RADNOR, Pa., April 14, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of its Non-Animal Navigator™ solution designed to help biopharmaceutical companies lead the transition ignited by the FDA's Roadmap to Reducing Animal Testing in Preclinical Safety Studies.
Positive
Seeking Alpha
10 days ago
The FDA's phase-out of animal testing for monoclonal antibody therapies boosts Certara's growth prospects, as evidenced by a 15% stock jump. Certara's recently posted a 14.1% revenue increase Y/Y, with significant contributions from biosimulation and Chemaxon businesses. Certara's cautious AI investments align with the FDA's regulatory changes, enhancing its end-to-end biosimulation offerings f...
More Certara News

Company Profile

Certara, Inc. engages in the provision of software and technology enables services for drug developers. It offers cell and gene therapy, clinical pharmacology, complex biologics, decision analytics and modeling, drug development and regulatory strategy, and model-based analysis services. The company was founded on June 27, 2017 and is headquartered in Princeton, NJ.

Head office United States
CEO William Feehery
Employees 1,546
Founded 2008
Website www.certara.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today